Skip to main content

Gain Therapeutics, Inc.

For the period ended Sep 30, 2025. Filed Nov 12, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 12, 2025

GANX$1.08-0.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Stockholders’ Equity (Unaudited)

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

​​​​​​​​​​​​​​​​​​
​ · ​ · Common Stock · ​ · AdditionalPaid-in · ​ · AccumulatedOtherComprehensive · ​ · Accumulated · ​ · ​ · ​
Three Months Ended September 30, 2025 · Shares · Amounts · Capital · Income (Loss) · Deficit · Total
Balance as of June 30, 2025​30,771,321​$3,078​$94,642,942​$584,083​$(91,534,053)​$3,696,050
Stock-based compensation (Note 15)​2,883​—​460,793​—​—​460,793
Exercise of warrants (Note 14)​25,300​​3​​41,742​​—​​—​​41,745
Changes in defined benefit pension plan obligation (Note 11)​—​—​—​5,308​—​5,308
Foreign currency translation​—​—​—​(26,170)​—​(26,170)
Issuance of shares and warrants in public offering (Note 14)​5,176,886​​518​​7,015,558​​—​​—​​7,016,076
Net loss​—​​—​​—​​—​​(5,284,373)​​(5,284,373)
Balance as of September 30, 2025​35,976,390​$3,599​$102,161,036​$563,221​$(96,818,426)​$5,909,430
​​​​​​​​​​​​​​​​​​
​ · ​ · Common Stock · ​ · AdditionalPaid-in · ​ · AccumulatedOtherComprehensive · ​ · Accumulated · ​ · ​ · ​
Nine Months Ended September 30, 2025 · Shares · Amounts · Capital · Income (Loss) · Deficit · Total
Balance as of December 31, 2024​27,132,588​$2,713​$88,779,318​$(247,549)​$(81,194,908)​$7,339,574
Stock-based compensation (Note 15)​97,952​9​1,414,429​—​—​1,414,438
Exercise of warrants (Note 14)​1,056,902​​108​​41,742​​—​​—​​41,850
Changes in defined benefit pension plan obligation (Note 11)​—​—​—​16,068​—​16,068
Foreign currency translation​—​—​—​794,702​—​794,702
Issuance of shares in ATM offering (Note 14)​2,512,062​​251​​4,909,989​​—​​—​​4,910,240
Issuance of shares and warrants in public offering (Note 14)​5,176,886​​518​​7,015,558​​—​​—​​7,016,076
Net loss​—​​—​​—​​—​​(15,623,518)​​(15,623,518)
Balance as of September 30, 2025​35,976,390​$3,599​$102,161,036​$563,221​$(96,818,426)​$5,909,430

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

​​​​​​​​​​​​​​​​​​
​ · ​ · Common Stock · ​ · AdditionalPaid-in · ​ · Accumulated Other Comprehensive · ​ · Accumulated · ​ · ​ · ​
Three Months Ended September 30, 2024 · ​ · Shares · ​ · Amounts · ​ · Capital · ​ · Income (Loss) · ​ · Deficit · ​ · Total
Balance as of June 30, 2024​25,172,573​$2,518​$84,710,747​$12,462​$(72,940,989)​$11,784,738
Stock-based compensation (Note 15)​25,811​2​352,015​—​—​352,017
Defined benefit pension plan adjustments (Note 11)​—​—​—​1,301​—​1,301
Foreign currency translation​—​—​—​229,047​—​229,047
Issuance of shares in ATM offering (Note 14)​426,786​​42​​615,473​​—​​—​​615,515
Issuance of shares and warrants in public offering (Note 14)​337,076​​34​​412,422​​—​​—​​412,456
Net loss​—​​—​​—​​—​​(4,485,692)​​(4,485,692)
Balance as of September 30, 2024​25,962,246​$2,596​$86,090,657​$242,810​$(77,426,681)​$8,909,382
​​​​​​​​​​​​​​​​​​
​ · ​ · Common Stock · ​ · AdditionalPaid-in · ​ · Accumulated Other Comprehensive · ​ · Accumulated · ​ · ​ · ​
Nine Months Ended September 30, 2024 · ​ · Shares · ​ · Amounts · ​ · Capital · ​ · Income (Loss) · ​ · Deficit · ​ · Total
Balance as of December 31, 2023​16,206,680​$1,621​$73,113,079​$247,241​$(60,783,717)​$12,578,224
Stock-based compensation (Note 15)​61,794​5​1,930,344​—​—​1,930,349
Exercise of stock options (Note 15)​15,983​​2​​57,709​​—​​—​​57,711
Exercise of warrants (Note 14)​1,797,380​​180​​113,621​​—​​—​​113,801
Defined benefit pension plan adjustments (Note 11)​—​—​—​3,477​—​3,477
Foreign currency translation​—​—​—​(12,882)​—​(12,882)
Net unrealized gain on available-for-sale securities (Note 5)​—​​—​​—​​4,974​​—​​4,974
Issuance of shares in ATM offering (Note 14)​426,786​​42​​615,473​​—​​—​​615,515
Issuance of shares and warrants in public offering (Note 14)​7,453,623​​746​​10,260,431​​—​​—​​10,261,177
Net loss​—​​—​​—​​—​​(16,642,964)​​(16,642,964)
Balance as of September 30, 2024​25,962,246​$2,596​$86,090,657​$242,810​$(77,426,681)​$8,909,382
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.